Loading
These experimental immune cells are designed to recognize TROP2 on cancer cells. Early trials are studying their safety and activity.
AACR 2026 abstract CT294 describes the TROPIKANA phase 1 protocol in advanced TROP2-positive solid tumors, with lymphodepletion and engineered cord-blood NK cells. It reports trial design and first treatment in January 2024, not a clinical response or survival result. NCT06066424 is recruiting with 54 planned participants. A separate colorectal minimal-residual-disease study, NCT06358430, combines this cell platform with cetuximab; it does not establish postoperative TNBC benefit.
Cord-blood natural killer cells engineered with a TROP2 CAR, IL-15 to support persistence, and an inducible caspase-9 safety switch. Connects to TROP2.
1.TROP2 CAR/IL-15 cord-blood NK cells slips into a pocket on TROP2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TROP2 CAR/IL-15 cord-blood NK cells" OR ABSTRACT:"TROP2 CAR/IL-15 cord-blood NK cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TROP2 CAR/IL-15 cord-blood NK cells, not a curated reading list.
Shares CAR-NK & CAR-macrophage, TROP2.
Shares CAR-NK & CAR-macrophage, TROP2.
Shares CAR-NK & CAR-macrophage, TROP2.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/